Abstract:1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea 3 Division of Endocrinology, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea 4 Division of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea 5 Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea 6 Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea 7 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea 8 Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Copyright © 2024 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Download PDF CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported. AUTHOR CONTRIBUTIONS Conception or design: J.H.H., K.A.H., J.H.H., H.A.S., E.G.H., J.M.Y., H.S.J., B.S.C. Acquisition, analysis, or interpretation of data: J.H.H., K.A.H., J.H.H., H.A.S., E.G.H., J.M.Y., B.S.C. Drafting the work or revising: J.H.H., K.A.H., J.H.H., H.A.S., E.G.H., J.M.Y. Final approval of the manuscript: J.H.H., K.A.H., J.H.H., H. A.S., E.G.H., J.M.Y., H.S.J., B.S.C. FUNDING This study was sponsored by Jeil Pharmaceutical Co. Ltd., Seoul, South Korea. The sponsor participated in the study design, data management, and analysis. Values are presented as mean±standard deviation or number (%). BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β-cell function; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OHA, oral hypoglycemic agent. Values are presented as mean±standard deviation unless otherwise indicated. HbA1c, glycosylated hemoglobin; LS, least square; SE, standard error; CI, confidence interval; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Values are presented as number (%). P <0.05 denotes statistical significance. TEAE, treatment-emergent adverse event; ADR, adverse drug reaction; AE, adverse event; NA, not available.

DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY

SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION

Comparative evaluation of metformin & sitaformin in classic PCOS patients undergoing intracytoplasmic sperm injection: A randomized controlled pilot study

Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS

Efficacy and Tolerability of Sitagliptin and Metformin Compared with Insulin As an Initial Therapy for Newly Diagnosed Diabetic Patients with Severe Hyperglycaemia

The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial

Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.

Acute pharmacodynamic responses to sitagliptin: Drug‐induced increase in early insulin secretion in oral glucose tolerance test

Efficacy of Adding Sitagliptin to Ongoing Metformin on Metabolic Profile, Triglyceride-Glucose Index, Vitamin D3, and Liver Tests in Patients Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment

Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS

1516-P: Free Fatty Acid and Amino Acid Predictors of Response to Metformin in Polycystic Ovary Syndrome

Efficacy and Safety of Sitagliptin (SITA)-Based Dual and Triple Combination Therapy in Older Chinese People with T2D

Pioglitazone as Add-on THERAPY in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial

Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches

Effects of GLP-1R agonist or co-cyprindiol, in combination with metformin, on polycystic ovary syndrome in overweight women: A Randomized Clinical Trial

Effect of Initial Intensive Insulin Therapy Followed by Sitagliptin on ? Cell Function in Patients with New Onset Type 2 Diabetes

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients

2320-PUB: Effects of Sequential Therapy Using Metformin plus Pioglitazone following Short-Term Intensive Insulin Therapy in Patients with Newly Diagnosed T2DM

Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis

Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis